二〇二四年四月二十四日 四川金石亚洲医药股份有限公司 董事会关于独立董事 2023 年度保持独立性情况 的专项意见 四川金石亚洲医药股份有限公司（以下简称"公司"）董事会根据《上市 公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等要求，就公司在任独立董事的独立性情况进行评估， 并出具如下专项意见： 经核查独立董事钟鹏、贾佑龙、刘初旺、赵小微的任职经历及其本人出具 的相关自查文件，公司董事会认为：上述人员未在公司担任除独立董事以外的 任何职务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存 在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立 董事独立性的情况。公司独立董事符合《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》中对独 立董事独立性的相关要求。 四川金石亚洲医药股份有限公司 董 事 会 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-010 四川金石亚洲医药股份有限公司 关于聘任证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第五届董事会第三次会议，审议通过了《关于聘任证券事务代表的议案》。 同意聘任王莹女士（简历见附件）为公司证券事务代表，与公司证券事务代表何 欣女士共同协助董事会秘书履行职责，任期与公司本届董事会任期一致。 王莹女士已参加深圳证券交易所组织的上市公司董事会秘书任前培训，并取 得上市公司董事会秘书培训证明，具备与其行使职权相应的任职条件，不存在《深 圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》规定的不得担任上市公司证券事务代表的情形。 公司证券事务代表王莹女士联系方式如下： 联系电话：028-87086807 传真：028-87086861 电子信箱：goldstone@goldstone-group.com 特此公告。 附件：王莹女士简历 ...

四川金石亚洲医药股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司(以下简称"公司")《2023 年年度报告》已 于 2024 年 4 月 26 日披露，为使投资者进一步了解公司的财务状况、经营情况及 公司发展规划，公司将于 2024 年 5 月 17 日(星期五)15:00-17:00 在全景网举行金 石亚药 2023 年度网上业绩说明会，本次说明会将采用网络远程方式举行，投资 者可登陆全景网"投资者关系互动平台"(http://ir.p5w.net)参与本次业绩说明会。 特此公告。 证券代码：300434 证券简称：金石亚药 公告编号：2024-012 出席本次说明会的人员有：董事长、总经理马益平、董事、副总经理、董事 会秘书林强、副总经理王志昊、财务总监王庆国、独立董事赵小微。 为充分尊重投资者，提升交流的针对性，现就公司金石亚药 2023 年度网上 业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者 可于 2024 年 5 月 16 日(星期四)1 ...

四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 （刘初旺） 本人刘初旺，自 2023 年 12 月 22 日经四川金石亚洲医药股份有限公司（以 下简称"公司"）2023 年第一次临时股东大会选举为公司独立董事。作为公司 独立董事，本人严格按照《公司法》、《上市公司独立董事管理办法》、《深圳 证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工作制度》 等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独立、勤勉 地履行职责，有效发挥独立董事的作用。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 (一)个人基本情况及工作履历 刘初旺，男，1967 年出生。上海财经大学财政学专业税务方向硕士、博士， 特华博士后科研工作站博士后，2005 年在南澳大利亚大学访学半年，现任浙江 财经大学财政税务学院副教授、税务专硕导师，兼任杭州市国际税收研究常务理 事，浙江大学经济学院、公共管理学院全国税务干部培训特聘讲师，2023 年 12 月至今担任四川金石亚洲医药股份有限公司独立董事。 (二)关于独立性 ...

本资产评估报告依据中国资产评估准则编制 四川金石亚洲医药股份有限公司拟对合并海南亚洲 制药股份有限公司形成的商誉进行减值测试所涉及 的资产组组合可回收价值 东洲评报字【2024】第 1004 号 （报告书及附件） 共 1 册 第 1 册 上海东洲资产评估有限公司 2024 年 4 月 8 日 资产评估报告 中国资产评估协会 资产评估业务报告备案回执 | 报告编码： | 3131020001202401037 | | --- | --- | | 合同编号： | 东洲评委（202402054）号 | | 报告类型： | 法定评估业务资产评估报告 | | 报告文号： | 东洲评报字【2024】第1004号 | | 报告名称： | 四川金石亚洲医药股份有限公司拟对合并海南亚洲 制药股份有限公司形成的商誉进行减值测试所涉及 | | | 的资产组组合可回收价值资产评估报告 | | 评估结论： | 1,907,000,000.00元 | | 评估报告日： | 2024年04月08日 | | 评估机构名称： | 上海东洲资产评估有限公司 | | 签名人员： | 李雨勤 （资产评估师） 会员编号：24120011 | | | ...

四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 作为四川金石亚洲医药股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工 作制度》等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独 立、勤勉地履行职责，有效发挥独立董事的作用，较好地维护了公司整体利益及 全体股东的合法权益。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 (一)个人基本情况及工作履历 缪建泉，男，1960 年 9 月出生，硕士。副主任中药师、执业中药师。曾任 福建省药材有限责任公司执行董事兼总经理；执行董事兼书记。现任福建省中药 材产业协会会长兼书记，2020 年 11 月至 2023 年 12 月担任四川金石亚洲医药股 份有限公司独立董事。 (二)关于独立性的情况说明 本人具备《上市公司独立董事管理办法》所要求的独立性，不存在影响独立 性的情况。 二、独立董事年度履职概况 (一)出席股 ...

四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 （朱建伟） 作为四川金石亚洲医药股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工 作制度》等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独 立、勤勉地履行职责，有效发挥独立董事的作用，较好地维护了公司整体利益及 全体股东的合法权益。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 (一)个人基本情况及工作履历 朱建伟，男，1956 年出生，美国国籍。上海交通大学"致远讲席教授"。 华东理工大学生化工程学士、上海医药工业研究院微生物药学硕士，上海医药工 业研究院微生物遗传学博士，美国 Hood 学院工商管理硕士（药事管理方向）。 1991 年 9 月至 1997 年 9 月在哈佛医学院 Joslin 糖尿病中心担任高级研究员，1997 年 9 月至 2014 年 6 月任美国 Frederick 国家癌 ...

四川金石亚洲医药股份有限公司 2023 年度财务决算报告 一、年度财务报告及审计情况 公司聘请立信会计师事务所（特殊普通合伙）审计公司及其子公司的 2023 年度财务报表， 审计了公司 2023 年 12 月 31 日的资产负债表和合并资产负债表、2023 年度的利润表和合并利润 表，2023 年度现金流量表和合并现金流量表，以及财务报表附注。立信会计师事务所（特殊普 通合伙）对上述审计范围内的公司均出具了标准无保留意见的审计报告，审计结果显示公司的财 务报表在所有重大方面按照企业会计准则的规定编制，公允反映了公司 2023 年 12 月 31 日合并 及母公司的财务状况以及 2023 年度合并及母公司的经营成果和现金流量。 如无特殊说明，下述描述和数据均为合并口径，单位：人民币元。 二、财务情况 （一）主要财务指标 | 项 目 | 2023 年 | 2022 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,209,199,438.06 | 1,242,603,080.88 | -2.69% | | 归属于上市公司股东的净利润（元） | 126,19 ...

Financial Performance - The company's total revenue for 2023 was approximately ¥1.21 billion, a decrease of 2.69% compared to ¥1.24 billion in 2022[30]. - Net profit attributable to shareholders was approximately ¥126.20 million, down 42.32% from ¥218.79 million in the previous year[30]. - The basic earnings per share decreased to ¥0.31, a decline of 42.59% from ¥0.54 in 2022[30]. - Operating cash flow net amount was approximately ¥151.14 million, down 53.21% from ¥323.04 million in 2022[30]. - Total assets at the end of 2023 were approximately ¥3.10 billion, an increase of 1.36% from ¥3.06 billion at the end of 2022[30]. - Net assets attributable to shareholders increased by 5.55% to approximately ¥2.40 billion from ¥2.27 billion in 2022[30]. - The company reported a significant decline in quarterly net profit, with a loss of approximately ¥12.58 million in Q4 2023[32]. - The company reported a non-operating income of CNY 12.09 million in 2023, down from CNY 23.03 million in 2022[36]. - The company received government subsidies amounting to CNY 7.9 million in 2023, compared to CNY 11.65 million in 2022[36]. - The company reported a total revenue of 8,327 million for the year, maintaining the same figure as the previous period[113]. Market Position and Competition - The company reported a significant reliance on its main products, with the sales revenue from the Kuaike cold medicine series accounting for a high percentage of total operating income and gross profit[6]. - The company is facing increasing competition in the domestic market due to rising health awareness and potential entry of foreign pharmaceutical companies[4]. - The OTC market for cold medicine is significant, with an estimated 1.043 billion people in China suffering from colds annually, indicating a strong demand for self-medication products[41]. - The health food market in China is projected to grow from CNY 211.3 billion in 2022 to CNY 286.7 billion by 2027, with a compound annual growth rate of 6.3%[42]. - The Chinese herbal medicine industry is expected to reach a market size of CNY 8 trillion by 2030, with an annual growth rate of 10.3% from 2016 to 2030[43]. Research and Development - The company has a diverse R&D pipeline, including integrated raw material drug formulations and calcium mineral series products, but faces risks related to drug development and approval processes[7]. - The company plans to expand its product line and enhance R&D capabilities in new composite pipeline technologies[30]. - The company is actively pursuing several R&D projects, including the consistency evaluation of diclofenac sodium sustained-release tablets, aimed at enhancing product competitiveness[66]. - The total R&D investment in 2023 was ¥50,011,112.66, representing 4.14% of operating revenue, an increase from 3.15% in 2022[70]. - The company is committed to research and development, although specific figures or projects were not disclosed in the report[116]. Quality Control and Compliance - The company has implemented strict quality control measures, exceeding national standards, but still faces risks related to product quality and potential economic losses[7]. - The company acknowledges the impact of national policies on the pharmaceutical industry, including price control measures that may affect profit margins[8]. - The company has no significant discrepancies between financial reports prepared under international and Chinese accounting standards[33][34]. - The company has implemented various internal control systems to enhance operational efficiency and risk management[151]. - The company has established a clear internal control system with defined roles and responsibilities to mitigate risks[152]. Strategic Initiatives - The company plans to distribute cash dividends of 1.10 RMB per 10 shares to all shareholders, based on a total of 401,743,872.00 RMB[9]. - The company has initiated significant investment projects, such as the Jinxi raw material drug project, which carries risks if not successfully completed[7]. - The company is focusing on market expansion strategies to improve overall performance in the upcoming fiscal year[30]. - The company aims to enhance brand loyalty and influence among future consumer groups through targeted marketing strategies[53]. - The company is committed to a marketing-driven approach to overcome current growth bottlenecks, utilizing a diverse product cluster strategy to balance commercial risks and expand market share[96]. Environmental Responsibility - The company adheres to various environmental protection laws and standards, ensuring compliance in its operations[162]. - The company has established a monitoring system for wastewater discharge, ensuring compliance with environmental regulations[170]. - The company has implemented a new strategy for wastewater treatment, focusing on reducing nitrogen and phosphorus pollution[170]. - The company has engaged third-party monitoring for pollutant emissions as part of its environmental compliance strategy[180]. - The company has committed to achieving carbon peak and carbon neutrality goals through structured environmental responsibility[181]. Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[106]. - The company held its first temporary shareholders' meeting on December 22, 2023, electing the fifth board of directors, which consists of 11 members, including 4 independent directors[103]. - The company has maintained compliance with governance standards, ensuring effective internal control and decision-making processes throughout the reporting period[102]. - The company has a governance structure in place with a mix of executive and independent directors, ensuring diverse oversight[113]. - The company has established a commitment to ensure that its shareholders, directors, supervisors, and senior management do not operate or assist in any competing business during their tenure[200].

Financial Performance - The company's revenue for Q1 2024 was ¥362,785,115.79, a decrease of 13.58% compared to ¥419,787,729.70 in the same period last year[4] - Net profit attributable to shareholders was ¥89,816,224.68, down 37.39% from ¥143,460,482.45 year-on-year[4] - Basic and diluted earnings per share decreased by 37.38% to ¥0.2236 from ¥0.3571 in the same quarter last year[4] - The net profit for Q1 2024 was CNY 89,543,650.31, a decrease of 37.1% compared to CNY 142,497,992.18 in Q1 2023[15] - Operating profit for Q1 2024 was CNY 115,048,924.11, down from CNY 184,249,348.46 in the same period last year, reflecting a decline of 37.6%[15] - Total revenue from sales in Q1 2024 was CNY 221,959,957.20, compared to CNY 350,792,078.64 in Q1 2023, indicating a decrease of 36.6%[17] - The total comprehensive income for Q1 2024 was CNY 89,543,650.31, compared to CNY 142,497,992.18 in Q1 2023, reflecting a decrease of 37.1%[16] Cash Flow and Assets - The net cash flow from operating activities was -¥90,480,979.33, representing a decline of 56.84% compared to -¥57,691,400.00 in the previous year[4] - Cash and cash equivalents decreased to CNY 444,143,577.19 from CNY 545,898,926.96, reflecting a decline of 18.5%[11] - The cash flow from operating activities for Q1 2024 was negative CNY 90,480,979.33, worsening from negative CNY 57,691,400.00 in Q1 2023[19] - The total current assets decreased to CNY 1,344,736,190.86 from CNY 1,371,587,670.56, a decline of 2.0%[12] - Total non-current assets increased to CNY 1,760,658,774.68 from CNY 1,729,850,994.45, an increase of 1.8%[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥3,105,394,965.54, a slight increase of 0.13% from ¥3,101,438,665.01 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 3.74% to ¥2,490,245,750.15 from ¥2,400,429,525.47[4] - Total liabilities decreased to CNY 591,785,286.41 from CNY 677,372,636.19, a reduction of 12.6%[13] - The total equity attributable to shareholders increased to CNY 2,490,245,750.15 from CNY 2,400,429,525.47, an increase of 3.7%[13] Operating Costs and Expenses - The total operating costs for the current period amount to CNY 247,274,368.45, an increase of 4.4% from CNY 236,336,112.04 in the previous period[14] - Research and development expenses decreased to CNY 8,503,028.08 in Q1 2024 from CNY 17,587,226.51 in Q1 2023, a reduction of 51.6%[15] - The company incurred financial expenses of CNY -1,432,158.76 in Q1 2024, compared to CNY -627,377.47 in Q1 2023, indicating an increase in financial costs[15] Market and Operational Insights - The overall market demand for cold medicine products stabilized in Q1 2024, contributing to the decline in revenue and profit[7] - The company experienced a decrease in sales prepayments, impacting the net cash flow from operating activities[7] - The company reported non-recurring gains of ¥2,172,349.82 during the quarter, including government subsidies and other income[5] - The company reported a significant reduction in employee compensation payable, decreasing to CNY 33,896,086.08 from CNY 75,786,697.07, a decline of 55.3%[13] - Inventory decreased to CNY 225,394,191.50 from CNY 238,164,264.61, a decrease of 5.2%[12] - Accounts receivable increased to CNY 100,957,025.89 from CNY 79,477,350.02, representing a growth of 27.1%[11]